摘要
目的为探讨乳腺癌患者血清IGF-I、CA153和IL-8水平的变化及临床意义。方法对36例乳腺癌组患者、40例乳腺良性病变组患者和35名正常人,用RIA法和ELISA法分别测定血清IGF-I、CA153和IL-8水平。结果乳腺癌组患者血清IGF-I、CA153和IL-8水平均高于乳腺良性病变组患者和正常组,差异有统计学意义(P<0.01);伴有淋巴结转移的乳腺癌患者血清IGF-I、CA153和IL-8水平明显高于无淋巴结转移的乳腺癌患者,差异有统计学意义(P<0.01)。结论乳腺癌患者血清IGF-I、CA153和IL-8水平的变化可能成为鉴别乳腺良、恶性病变的辅助指标之一,有助于判断乳腺癌有无淋巴结转移及预后。
Objective To explore the clinical significance of serum IGF-I, CA153 and IL-8 levels in patients with breast cancer. Methods The serum levels of IGF-I, CA153 and IL-8 in 36 patients with breast cancer, 40 patients with benign breast patients and 35 healthy controls were determined by RIA and ELISA respectively. Results The serum levels of IGF-I, CA153 and IL-8 in patients with breast cancer were significantly higher than those in benign breast patient and controls （P 〈0. O1 ）. The serum levels of IGF-I, CA153 and IL-8 in 15 breast cancer patients with lymph node metastasis were significantly higher than those in 21 breast cancer pa- tients without lymph nodes metastasis （P 〈0.01 ）. Conclusion The serum levels of IGF-I, CA153 and IL-8 might be used as markers in differential diagnosis of malignant from benign diseases, also might be helpful for lymph nodes metastasis prediction.
出处
《标记免疫分析与临床》
CAS
2013年第4期218-220,共3页
Labeled Immunoassays and Clinical Medicine
